Pyr-T
Pyr-T, also known as N,''N-tetramethylenetryptamine or as 3-indole, is a lesser-known serotonin receptor modulator of the tryptamine and pyrrolidinylethylindole families. It is the cyclized derivative of diethyltryptamine in which the N'',N-diethyl groups have been fused into a pyrrolidine ring.
Use and effects
In his 1997 book TiHKAL, Alexander Shulgin reported neither the dose range nor the duration of the drug. However, individual experiments employed 25 to 50mg orally and 70mg smoked. Pyr-T produced effects including malaise, feeling sick, unpleasantness, salivation, muscle and joint pains, dizziness, feeling high, and uncomfortableness. Hallucinogenic effects, for instance visuals, were either absent or minor.Pharmacology
Pharmacodynamics
Pyr-T has been found to show affinity for serotonin receptors, including the serotonin 5-HT1A, 5-HT2A and 5-HT2C receptors. Its affinities for these receptors were 30nM for the serotonin 5-HT1A receptor, 110nM for the 5-HT2A receptor, and 750nM for the serotonin 5-HT2B receptor. The affinities of pyr-T for the serotonin 5-HT2A and 5-HT2B receptors were similar to but slightly lower than those of dimethyltryptamine, whereas its affinity for the serotonin 5-HT1A receptor was 5.7-fold higher than that of DMT and was intermediate between those of DMT and 5-MeO-DMT. The serotonin 5-HT1A to 5-HT2A receptor affinity ratios in the study were about 0.27 for pyr-T, 0.5 for 5-MeO-DMT, 1.4 for bufotenin, 2.3 for DMT, and 32 for psilocin.Pyr-T has been found to produce behavioral changes in animal tests. It was described as being as potent as diethyltryptamine in rodents, cats, and primates, but that it also had a poor margin of activity relative to toxicity and was unlikely to be tested in humans. It has been found to produce hypolocomotion in rodents. Conversely, pyr-T failed to acutely produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.